Mobile Menu - OpenMobile Menu - Closed

Health

Committee activity related to implementation of the Affordable Care Act; health insurance company practices; Medicare and Medicaid; prescription drugs; chronic and infectious diseases; reproductive and women’s health; and the safety of America’s food supply. 

More on Health

Mar 28, 2017 Press Release
Pallone spoke of the importance of a prompt reauthorization of the Medical Device User Fee Amendments.
Mar 28, 2017 Hearing

The Subcommittee on Health will hold a hearing on Tuesday, March 28, 2017, at 10:15 a.m. in 2123 Rayburn House Office Building.  The hearing is entitled “Examining FDA’s Medical Device User Fee Program.” 

 

Mar 24, 2017 Press Release
Pallone on Speaker Ryan abruptly ending consideration of TrumpCare in the U.S. House of Representatives
Mar 24, 2017 Press Release
Energy and Commerce Committee Ranking Member Frank Pallone, Jr. (D-NJ) delivered the following remarks on the House Floor today during consideration of TrumpCare, the Republican bill to repeal the Affordable Care Act
Mar 23, 2017 Press Release
Energy and Commerce Committee Ranking Member Frank Pallone, Jr. (D-NJ) released the following statement after the Congressional Budget Office (CBO) issued an updated score detailing the effects of TrumpCare
Mar 22, 2017 Press Release
Pallone and Senate Finance Committee Ranking Member Wyden released new information about the impact of TrumpCare on Medicare Part B premiums.
Mar 22, 2017 Press Release
Health Subcommittee Ranking Member Gene Green spoke about the success of PDUFA and the need to quickly reauthorize the agreement.
Mar 22, 2017 Hearing

The Subcommittee on Health will hold a hearing on Wednesday, March 22, 2017, at 10:15 a.m. in 2322 Rayburn House Office Building.  The hearing is entitled “Examining FDA’s Prescription Drug User Fee Program.”  

 

Mar 21, 2017 Press Release
Pallone emphasized that the Republican TrumpCare proposal will sabotage efforts to address the national opioid epidemic.
Mar 21, 2017 Hearing

The Subcommittee on Oversight and Investigations held a hearing on Tuesday, March 21, 2017, at 10:15 a.m. in 2123 Rayburn House Office Building.  The hearing is entitled “Fentanyl: The Next Wave of the Opioid Crisis.”